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Background : Cyclosporine A (CsA) is inconstantly effective in inducing remission in acute attacks of 
ulcerative colitis (UC) not responding to steroids.. This study aimed to establish whether multidrug resistance 
gene (MDR)1 polymorphisms would be associated with CsA failure. 
Patients and Methods : The distribution of the different genotypes of single nucleotide polymorphisms (SNP) 
G2677T/A and C3435T of MDR1 exons 21 and 26, respectively, was studied in 154 patients (mean age, 44 yr) 
who had received CsA to treat severe attacks of steroid resistant UC in 11 centers in France and Belgium. 
Patients were classified as CsA failure (n = 50) when they needed colectomy within 30 days after CsA initiation. 
The SNPs were detected by use of a 5' nuclease allelic discrimination assay. 
Results : There was a significant association between the G2677T/A polymorphism distribution (exon 21) and 
the risk for CsA failure (P = 0.0001). The TT genotype of exon. 21 was significantly associated with the risk 
compared with the two other genotypes (odds ratio, 3.77; 95% confidence interval, 1.42-9.97, P = 0.007). There 
was no significant association between the genotype C3435T distribution (exon 26) and the risk of CsA failure 
(P = 0.23). 
Conclusion : The TT genotype of exon 21 MDR1 polymorphisms is associated with a higher risk of CsA failure 
in patients with steroid resistant UC. Further studies should be performed to establish whether other treatments 
could be more efficient to avoid surgery in this subset of patients. 
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Severe attacks of ulcerative colitis (UC) are a life-threatening condition, and the first line treatment relies on high 
doses of corticosteroids.1,2 Cyclosporine A (CsA) has been shown to be effective to avoid early colectomy in 
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approximately two thirds of the patients with steroid resistance;3 however, this drug has potential risks including 
renal insufficiency, hypertension, and opportunistic infections.4 Infliximab has recently been shown to be also 
effective in this setting.5 Finding predictors for efficacy or failure of these drugs may certainly help the clinician 
to make treatment decisions. 
The metabolism of CsA has a high inter-individual variability.6 CsA is a substrate of P-glycoprotein (P-gp), a 
transporter expressed at the surface of epithelial and lymphoid cells that is encoded by the multidrug resistance 
gene (MDR)1. Single nucleotide polymorphisms (SNP) have been found in various regions of the MDR1 gene. 
They include SNP G2677T/A in exon 21 and SNP C3435T in exon 26.7 It has been suggested that the TT 
genotype of C3435T SNP is a predisposing factor for UC, extensive lesions,8-10 and a higher risk of colectomy.11 
A recent study searched for correlations between the MDR1 polymorphisms and drug resistance in IBD; 
however, the statistical power was too low to exclude any correlation with CsA efficacy because only 11 patients 
of this series had received this drug.12 
To test the hypothesis that MDR1 polymorphisms would be predictive of CsA resistance in patients with severe 
attacks of steroid resistant UC, we compared the distribution of the different SNPs of MDR1 exons 21 and 26 in 
a large series of patients presenting with steroid resistant severe UC necessitating CsA therapy and who were 
classified as responded or resistant to CsA on the basis of the need of colectomy within the 30 days after CsA 
initiation. 
PATIENTS AND METHODS 
This study was performed in 11 IBD clinics of the GETAID (Groupe d'Etudes Thérapeutiques des Affections 
Inflammatoires Digestives) in France and Belgium. Patients who had been treated by CsA for severe steroid 
resistant UC were retrospectively identified. Inclusion criteria were a past history of an acute steroid resistant 
flair of UC requiring CsA rescue therapy (2-4 mg/kg/d) and a follow-up after CsA. Patients with Crohn's disease 
and indeterminate colitis were excluded. CsA failure was defined as the need for colectomy within 30 days after 
the start of CsA. Patients who were not colectomized within the first 30 days were considered as "responders." 
We collected information on the disease extent, duration of UC and of the present flare, smoking, as well as the 
number of bloody stools per day, and C-reactive protein (CRP), which have been previously shown to be 
associated with the risk of colectomy.13 
The methods used to monitor CsA blood levels differed between centers, so the results could not be pooled. 
Thirty-two patients from a single institution had a similar monitoring (EMIT 2000 cyclosporine assay, Dade-
Behring, Roche CO-BAS Mira, Liederbach, Germany). Correlations between the blood CsA level, CsA doses, 
the risk for colectomy, and the MDR1 genotypes were studied in this subgroup of patients. 
Blood samples were collected for genotyping after obtaining a written informed consent by the patients. 
Genotyping was performed using Taqman method. The SNPs of MDR1 exon 21 and exon 26 (3435C > T) were 
detected by use of a 5' nuclease allelic Discrimination assay (ABI PRISM 7700 Sequence Detection System; 
Applied Biosystems, Foster City, CA). The sequences of the primers and specific probes were labeled with the 
fluorescent reporter dyes FAM and VIC at their 5' extremities. The MDR1 SNPs and two-locus haplotype 
associations were studied as previously described.14,15 
Statistical Analysis 
Quantitative variables were expressed as mean ± standard deviation. Statistical analysis was performed using 
Stat-view 5.0 software for Windows (SAS Institute, Inc., 1992-1998, Cary, NC). Distributions of qualitative 
variables were compared between groups by the chi-square test; distributions of quantitative parameters were 
compared between groups by parametric or nonparametric tests depending on the normality of the variables 
tested (Wilks-Shapiro test). Results were expressed with odds ratio (OR) and 95% confidence intervals (95% 
CI). For each analysis, P values less than 0.05 were considered to be statistically significant. All variables with a 
P value less than 0.20 on univariate analysis were included in a logistic regression model to determine ORs for 
CsA resistance. The goodness of fit was verified by the Hosmer-Lemshow test. 
RESULTS 
One hundred fifty-four patients responding to the inclusion criteria participated in the study. Their characteristics 
are summarized in Table 1. Fifty-five (33%) patients were colectomized within the first 30 days after CsA 
initiation. CsA failure patients did not differ from CsA responders for age, sex, disease extent or duration, and 
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smoking history (Table 1). Data for genotyping of exons 21 and 26 were finally available for 150 and 153 
patients, respectively. The mean duration intravenous CsA use was 8 (range, 1-23) days and 103 (range, 6-684) 
days for oral CsA. 
Allele and genotype frequencies in the different groups are shown in Tables 2 and 3. The distribution of MDR 
polymorphism were in close agreement with that predicted by the Hardy Weinberg equilibrium (χ2 = 0.27, P = 
0.80 for exon 21 and χ2 = 0.19, P = 0.43 for exon 26). There was a significant association between the 
G2677T/A polymorphism distribution and the risk of CsA failure (P = 0.0001) (Table 2). The TT genotype of 
exon 21 was significantly associated with the risk of CsA failure compared with the other genotypes (OR, 3.77; 
95% CI, 1.42-9.97; P = 0.007). There was no significant association between the genotype C3435T distribution 
(exon 26) and the risk of CsA failure (P = 0.23) as well as for the TT genotype of exon 26 (OR, 1.58; 95% CI, 
0.72-3.46, P = 0.25) (Table 3). No statistically significant difference was found in two-locus haplotype 
distribution between CsA resistant patients and responders (data not shown). 
 









Age in years, mean (SD) 44.4 (14.4) 45.8 (15.7) 43.5 (13.9) 
Male (%) 54 48 57 
Disease extent (%)    
Distal 3 0 3 
Left colon 17 12 20 
Pancolitis 80 88 77 
Disease duration in months, mean (range) 63(0-367) 77 (0-223) 57 (45-367) 
Flare duration in days, mean (range) 47 (5-223) 54 (6-57) 44 (5-78) 
Smoking status (%)    
Never 65 60 65 
Ex-smokers 28 30 29 
Smokers 7 10 6 
CsA = cyclosporine A; SD = standard deviation. 
 






No. 49 101 150 
Allele frequency G (%) 54.6 63.3 62.3 
Allele frequency T (%) 45.4 36.7 37.7 
GG (%) 44.9 34.3 38 
GT or GA* (%) 30.6 57.8 48.7 
TT* (%) 24.5 7.9 13.3 
*Genotyping was feasible in 150 patients; only 5 patients had the GA genotype, no AA or TA genotypes; GA and GT were considered as one 
group. CsA = cyclosporine A. 
 






No. 49 104 153 
Allele frequency C (%) 53.1 53.3 53.3 
Allele frequency T (%) 46.9 46.7 46.7 
CC (%) 34.6 26.7 29.4 
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CT (%) 36.7 53.3 47.7 
TT(%) 28.7 20 22.9 
CsA = cyclosporine A. 
 
Variables Predictive of CsA Failure 
With sue of univariate analysis, CsA resistant had, in comparison with patients responsive to CsA therapy, 
higher CRP level (76.4 ± 8.5 mg/L vs. 53.4 ± 4.5; P = 0.001) and higher number of bloody stools (10.0 ± 4.5 vs 
8.3 ± 3.0; P = 0.01) at baseline. In multivariate analysis, CRP levels (OR, 1.008; 95% CI, 1.001-1.0017; P = 
0.04), the number of bloody stools (OR, 1.12; 95% CI, 1.004-1.251; P = 0.04), and exon 21 genotype TT (OR, 
6.75; 95% CI, 1.53-29.71; P = 0.01) remained significantly and independently predictive of response to CsA. 
Genotypes and CsA Doses and Blood Concentrations 
In the 32 patients from a single institution who had the same protocol to measure blood CsA levels, 16 (50%) 
patients needed early colectomy. No significant difference was found in this subgroup in terms of mean CsA 
daily dose, CsA weight adjusted dose, and mean CsA blood level between the CsA resistant and responders and 
neither between the various genotypes of exons 21 and 26 (Table 4). However, during treatment, the CsA dose 
tended to be adjusted differently according to the exon 21 genotype (Wilcoxon rank sum test, P = 0.08). The 
CsA dose was decreased in only 1 patient of 7 with the TT genotype versus 12 of 24 patients with other exon 21 
genotypes. Concomitantly, the mean blood CsA level remained stable in genotype TT patients (from 289 ± 146 
to 291 ± 77 ng/mL), whereas it decreased in the patients with other exon 21 genotypes (from 281 ± 83 to 229 ± 
100 ng/mL, P = 0.07). In other terms, the lack of response to CsA observed in patients with the exon 21 
genotype TT was not the consequence of an insufficient CsA dose but was observed in spite of an increasing 
CsA dose. 
 
TABLE 4: Comparison of CsA Doses and Serum Concentrations According to Different Genotypes of SNPs 
C3435T (Exon 26) and G2677T/A (Exon 21) (n = 32) 
 MDR1 Exon 26 MDR1 Exon 21 
 CC CT TT GG GT TT 
Serum CsA concentration, ng/mL 264.0 (31.9) 261.1 (22.3) 328.7 (39.1) NS 272.4 (20.8) 258.2 (16.8) 302.1 (40.2) NS 
IV CsA dose, mg/d 126.2 (10.7) 137.7 (19.6) 139.3 (13.4) NS 136.8 (21.0) 128.8 (16.2) 144.3 (13.6) NS 
IV CsA dose/body weight, mg/kg/d 2.0 (0.1) 2.23 (0.3) 2.29 (0.2) NS 2.0 (0.1) 2.23 (0.3) 2.29 (0.2) NS 
Results are expressed as means (standard deviation). CsA = cyclosporine A; IV = intravenous. 
 
DISCUSSION 
The present study shows a significant association between MDR1 polymorphism and the resistance to CsA in 
patients presenting with steroid resistant UC. Namely, the polymorphisms of G2677T/A in exon 21 SNP, and 
especially the TT genotype, were significantly associated with an increased risk of resistance to CsA. The 
frequency of the genotypes of exons 21 and 26 SNPs of the MDR1 gene in our cohort was consistent with 
previous studies.16,17 
CsA is a substrate of P-gp encoded by the MDR1 gene and presents high interindividual pharmacokinetic 
variability. The MDR1 gene has been shown so far to play a role in determining disease susceptibility and 
disease behavior in IBD. The hypothesis that altered P-gp expression in IBD patients could modify the response 
to medical therapy was assessed by Farrell et al.18 Peripheral blood lymphocytes from patients with UC or 
Crohn's disease with previous bowel resection for medical treatment failure had a higher P-gp expression 
compared with patients with inactive disease. In contrast, Langman et al19 reported that MDR1 gene expression 
was down-regulated in colonic tissue of UC patients. Several studies have suggested that the TT genotype of 
C3435T SNP in exon 26 is a predisposing factor to UC, with pan colonic involvement,8-10 and could predict the 
need for colectomy.11 These studies did not look at potential correlations between these markers and the 
resistance to CsA. Recently, Palmieri et al12 found that MDR1 polymorphisms had no significant role in disease 
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susceptibility and response to medical therapy in their Italian population of inflammatory bowel disease patients. 
Nevertheless, there were only 11 patients treated by CsA. Two other large population-based case-control studies 
failed to show a significant association between C3435T MDR1 gene polymorphism and predisposition to 
UC.20,21 but did not assess response to treatment. Our study, which included a large number of patients treated 
with CsA, identified genotype TT of exon 21 as a powerful predictor of CsA failure, whereas the TT genotype of 
exon 26 was not predictive. The role of exon 26 C3435T on CsA pharmacokinetics has been controversial in the 
literature. Several studies found no correlation between these two parameters in renal transplant recipients,22-26 
but a recent study found that exon 26 C3435T influenced the dose of CsA to be administered to achieve the 
target concentration in the serum of liver transplant recipients.27 We found no significant correlation between the 
C3435T and G2677T/A polymorphism and the CsA levels or the CsA dose; however, the subset of patients for 
whom CsA dosages were available for correlation analysis was limited (n = 32). 
There is controversy regarding the effects of polymorphism G2677T/A on MDR1 transport activities. This 
polymorphism could be in linkage disequilibrium, with a polymorphism elsewhere in the genome that modifies 
MDR1 expression or function.7 Some evidence linking this polymorphism to IBD susceptibility already exists. 
Brant et al28 found a significant association of the Ala893 variant (G2677) of the tri-allelic G2677T/A SNP 
(Ala893Ser/Thr) of exon 21, known to decrease transporter function, with Crohn's disease; a nonsignificant trend 
was also found in UC patients. Likewise, an association with the T allele (893Ser variant) of exon 21 was found 
in UC patients by Potocnik et al.29 Two intronic SNPs in linkage disequilibrium with exons 21 and 26 haplo-
type, one in intron 13 (rs2235035) and another in intron 16 (rsl922242), were significantly associated with 
refractory Crohn's disease (P = 0.026, OR, 2.7 and P = 0.025, OR 2.8, respectively), as well as with UC (P = 
0.006, OR 1.8 and P = 0.026, OR 1.9, respectively). Ho et al9 did not find an association between G2677T/A 
SNP polymorphism and IBD; however, a two-locus haplotype (3435T/G2677) was significantly associated with 
UC in their study. They reported a nonsignificant increase in the frequency of exon 26 TT genotype in UC 
patients requiring colectomy (as also noticed in our series). 
The classical pharmacogenetic model whereby high MDR1 expression may mediate drug resistance in IBD 
appears countered by the fact that low MDR1 expression could be associated with increased susceptibility to 
IBD. Sambuelli et al30 found a high expression of P-gp in the mucosa of patients with refractory UC. In addition, 
a recent study suggested that MDR1 genotypes determine early onset and severe course of disease in UC.31 The 
finding that mdr1a-knockout mice develop a UC-like colitis that can be prevented by antibiotics suggests that P-
gp-170 may have a defensive barrier function against microbial products or components.7 Our study was 
designed to establish whether MDR1 polymorphisms could help predict CsA response in UC patients failing 
steroids but not to search for a possible role in disease susceptibility because it did not include a control group of 
normal patients. 
Using logistic regression analysis, we identified the number of bloody stools, CRP level, and exon 21 TT 
genotype as independent predictive variables of therapeutic response to CsA. CRP level and the number of stools 
have already been described as predictors of a high risk for surgery in patients with severe UC treated with 
steroids,12 and physicians probably largely use these criteria to make treatment decisions. Interestingly, the OR 
associated with exon 21 TT genotype was far greater than those associated with CRP and number of bloody 
stools, underscoring perhaps its positive predictive value in estimating the risk of CsA failure. Moreover, no 
significant statistical interaction was found between this genotype and CRP or number of bloody stools. 
In conclusion, our preliminary study supports the hypothesis that exon 21 polymorphisms of MDR1 gene may be 
considered as predictors of response to medical therapy in patients with acute steroid resistant UC and who 
receive CsA. Further studies with larger adequate sample size should be performed to establish whether they can 
help in making difficult treatment decisions, especially in choosing among surgery, CsA, and infliximab. 
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